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Description of decision model 
 The decision model considers a hypothetical cohort of 10,000 recent immigrants, aged ≤35, 
arriving in the United Kingdom. Eligibility for LTBI screening is predicated on the migrant’s age 
(whether <16 or 16-35 years) and tuberculosis (TB) incidence in their country of origin (using 
increments of 50/100,000) as shown in online supplementary table 1. 
 Depending on the incidence threshold at which screening is instigated, a proportion of these 
migrants are eligible to be screened and undergo interferon gamma release assay (IGRA) testing which 
will yield either a positive or negative result. In our multi-centre cohort, which we use to parameterise 
our model, the proportion of indeterminate results was low (0.16%). Therefore, we assumed that the 
indeterminate rate was negligible in this hypothetical model cohort. A proportion of the immigrants 
who are not eligible to be tested at a specific threshold will also have LTBI and remain at risk of 
progressing to active TB; those immigrants who are ineligible, and uninfected, have no further sequelae 
in the model. 
 Individuals who are IGRA positive (which can be either true or false positive) will go on to be 
assessed for active TB with chest radiography. As a simplification it is assumed that there are no 
prevalent cases of active TB identified in the immigrant cohort at the time of screening. In reality, 
however, a very small proportion of migrants will have active TB (0.3% in our cohort). Nonetheless, 
this is extremely rare and in most cases, the chest radiograph/assessment for active TB will be normal 
and the immigrant will be offered chemoprophylaxis with 3 months of rifampicin and isoniazid.  
 A proportion of the true and false positive individuals commence therapy. Amongst these 
individuals who do commence therapy, a proportion will develop drug-induced liver injury even 
though this is rare (0.2%1) in the age-group we considered (immigrants ≤35 years). In those who 
develop drug induced liver injury (DILI), extra costs in the form of additional clinic visits, inpatient 
admission and blood tests are required. Eventually, chemoprophylaxis will need to be stopped in a 
small proportion as the drug induced liver injury will not improve. It is assumed that these individuals 
will have only completed four weeks of therapy and so the efficacy of the chemoprophylaxis is 
negligible. Therefore these individuals remain latently infected and thus at future risk of progressing to 
active TB disease. However, in the vast majority, the drug induced liver injury will usually improve. In 
those individuals where the liver function tests return to normal, treatment will be (re)continued and 
defined proportions will complete and not complete therapy.  
 In those individuals who do not develop DILI, uncomplicated treatment will ensue with fixed 
proportions completing and not completing therapy. 
 Complete treatment will have a 65% efficacy in preventing progression from LTBI to active 
TB.2 This means that there will be some patients who complete therapy but in whom the drug regimen 
has been ineffectual. As an added layer of complexity it is assumed that the proportion of immigrants in 
whom hepatotoxic effects have improved but do not complete therapy will have completed 50% of the 
drug regimen (ie. 6 weeks) and, based on data suggesting equivalence of 3 months of rifampicin and 
isoniazid and 6 months isoniazid, we assume, in keeping with previous authors3 4, that this reduces the 
risk of reactivation by 21%.2 It is important to note that therapy is only efficacious in truly infected 
individuals and is of no benefit (in terms of preventing reactivation to active TB) for those immigrants 
who test false-positive with the IGRA. 
 In those individuals, who are true positive, who have completed chemoprophylactic therapy 
(either fully or partially) which has been successful we assume that infection with Mycobacterium 
tuberculosis is cleared (“Clearance of M. tuberculosis infection”) with no further sequelae for these 
individuals. However, if therapy has not been successful (“Non-clearance of M. tuberculosis 
infection”) it is assumed that the individuals have not cleared M. tuberculosis infection and so remain 
latently infected. Over the time horizon of the model, these individuals can either “remain in LTBI 
state” or “reactivate to active TB disease”. False-positive individuals, whether or not they completed 
the therapeutic course, are not actually infected and so there are no further sequelae. 
 Immigrants with negative IGRA results are assumed to be uninfected and will be discharged 
from the screening clinic. For those individuals who are truly uninfected no further costs or effects are 
incurred following screening. In contrast, individuals who are false-negative actually have LTBI and 
are at risk of progressing to active TB disease (with its attendant costs) over the 20-year horizon of the 
model. In fact, it is important to note that a number of different groups within the immigrant cohort will 
have LTBI and remain at risk of progressing to active TB disease over the time horizon of the model 
including: 
 
1. Immigrants with LTBI who are not eligible to be screened as they originate from a country 
with a TB incidence which does not meet the screening criteria (eg. an individual arriving 
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from India (TB incidence 170/100000) but screening is limited to individuals arriving from 
countries with a TB incidence ≥200/100,000. 
2. Immigrants with LTBI who screen positive but decline to commence chemoprophylaxis. 
3. Immigrants with LTBI who screen positive, accept chemoprophylaxis, do not develop 
hepatotoxicity, complete therapy but it is not effective.  
4. Immigrants with LTBI who screen positive, accept chemoprophylaxis, do not develop 
hepatotoxicity do not complete therapy which is not effective. 
5. Immigrants with LTBI who screen positive, accept chemoprophylaxis, develop hepatotoxicity 
which resolves, complete therapy but it is not effective.  
6. Immigrants with LTBI who screen positive, accept chemoprophylaxis, develop hepatotoxicity 
which resolves, do not complete therapy but it is not effective. 
7. Individuals with LTBI who screen positive, accept chemoprophylaxis, develop hepatotoxicity 
which does not resolve resulting in them stopping therapy early. This renders them still 
latently infected. 
8. Immigrants with LTBI but who actually test false-negative with the IGRA. 
 
 
 These individuals remain at risk of progressing from the latent state to active TB disease at a 
fixed rate. In the absence of reliable data about the proportion of migrants with HIV infection it is 
assumed that none of the immigrants have HIV.  
 If an individual with LTBI breaks down to active TB disease all strains are assumed to be 
fully drug sensitive. Individuals with active TB are modelled to have a fixed number of contacts which 
will result in a fixed number of secondary active TB cases and LTBI. Depending on the severity of 
disease, a proportion of individuals will need to be hospitalised whilst the remainder will be managed 
as outpatients. It is assumed that all subjects accept treatment and that treatment for all cases of active 
TB follows national guidelines with compliance, and cure, fixed at 100%. Once an individual has been 
treated for active TB they cannot be re-infected during the course of the 20 year model. In view of the 
low mortality rate from TB in the UK it is assumed that there is no TB/background mortality during the 
20-year horizon of the model. 
 
Input parameters and probabilities 
Input data were obtained from the present multi-centre study whilst probabilities for transitioning 
between states were obtained from previous literature(see online supplementary table 2).  
 Key to the cost-effectiveness analysis were the parameters used to describe the performance of 
the IGRA (QuantiFERON-Gold In-tube) in diagnosing LTBI. These were obtained from the most 
recent meta-analysis on IGRA performance which concluded the QuantiFERON Gold In-tube has a 
specificity of 99% and sensitivity, in developed countries, of 84%.5 The high specificity means that the 
proportion of false-positive results is relatively small, given the relatively high prevalence of LTBI in 
the cohort. 4 6 In contrast, the sensitivity of the IGRA impacts on the proportion of false-negative 
results. 
 When calculating the true prevalence of LTBI in the tested cohort, it is important to take into 
account test performance. If, for example, 20% of individuals are IGRA positive it would be 
incorrect/inaccurate to simply assume that these 20% represent all truly infected individuals. The 
reason for this is that, depending on test sensitivity and specificity, a proportion of positives will be 
falsely-positive whilst some negatives will be falsely-negative. We therefore calculated the true 
prevalence of LTBI in the cohort by using the following formula: 
 
Probability of a positive result = (Test sensitivity*Prevalence of LTBI) + ((1-Test specificity)*(1-
Prevalence)) 
 
Rearranging for Prevalence of LTBI, the formula becomes: 
 
Prevalence of LTBI = Probability of a positive result – (1-Test specificity)/((Test sensitivity)-(1-Test 
specificity)) 
 
This is important because, returning to our example of 20% of individuals being IGRA positive when 
test performance suggests a sensitivity of 84% and specificity of 99%, the true prevalence is actually 
22.9%. 
 Another important, but poorly understood, parameter was the rate at which immigrants with 
LTBI reactivated and progressed to active TB disease. Although immigrants should, in theory, have a 
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lower rate of progression than recent contacts of smear-positive tuberculosis, it could be argued that 
those individuals arriving from high TB burden countries are, in fact, akin to recent contacts as they 
will have been recently and repeatedly exposed to individuals with infectious tuberculosis. This makes 
it difficult to parameterise the progression rate with full certainty. For example whilst Marks et al 
calculated 6.7% progression over a 40 year period in TST positive (>15mm) Southeast Asian refugees7, 
data from the UK, in a predominantly Southeast Asian population suggests that over a 10 year period 
approximately 13% of TST positive, untreated, immigrants (primarily from the Indian Subcontinent) 
will go on to develop active TB.8 Horsburgh estimated that in 16-35 year olds with a >15mm TST (not 
recently converted) the annual risk of reactivation was 0.19%.9 If the skin test was >15mm and there 
was recent conversion then the annual risk of reactivation would 0.56%.9 In view of the large 
difference in published data we assumed that 5% of the cohort with LTBI, in the absence of 
chemoprophylaxis, would progress to active TB over the 20 year time horizon; a suitably wide range 
was explored in the sensitivity analysis. 
 
Costs 
Component costs considered were primarily direct costs obtained from economic evaluations 
conducted for the UK NICE TB guidelines1, and its forthcoming update, uplifted to 2010 prices(see 
table 2 for costs) using the Consumer Prices Index. In the present analysis, indirect costs such as 
transportation and loss of earnings by patients were not considered. Both costs and non-monetary 
health effects were discounted at an annual rate of 3.5%, which reflects UK Treasury and NICE 
recommendations.10 11 
 
Effects 
The main effects considered in the model were the number of cases of active tuberculosis that would be 
predicted to occur over the 20-year time horizon and the number needed to treat (in other words the 
number of individuals that need to be treated for LTBI) to prevent one case of active TB. 
 
Cost-effectiveness 
As recommended by the Panel of Cost-effectiveness in Health and Medicine, the comparative 
performance of the different screening protocols was measured using the Incremental Cost-
effectiveness ratio (ICER – see equation 1) which quantifies the trade-offs between switching from one 
competing, mutually-exclusive, intervention to another.12 The higher the ICER, the less cost-effective 
the intervention is.  
  
rotocolBscreeningprotocolAscreeningp
rotocolBscreeningprotocolAscreeningp
essEffectivenessEffectiven
CostCost
ICER 
  
 
Sensitivity analysis 
Parameter uncertainty can potentially affect the results of the cost-effectiveness analysis. A simple one-
way sensitivity analysis was therefore undertaken to explore the impact that changes in all key 
parameters and costs had on the number of cases of active TB occurring over 20 years, the costs and 
the associated ICERs. 
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Supplementary table 1. Screening thresholds considered in the cost-effectiveness analysis 
 
Screening threshold for immigrants (number of cases of TB/100,000)1 
Under 16 16-35 years 
None None 
40 500 
40 450 
40 400 
40 350 
40 300 
40 250 
40 500+SSA2 
40 200 
40 150 
40 100 
40 40 
All All 
 
1Refers to TB incidence in the country of origin 
2Sub-Saharan Africa 
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Supplementary table 2. Parameters used as input values in the decision model 
 
Probabilities Base case (range)1 References 
 
IGRA positivity/prevalence of LTBI in under 35 year old cohort 
 
 
Varies (table 2 in main text)  
 
Current 
study 
Proportion undergoing screening Varies (table  3 in main text)  
Specificity of QuantiFERON 0.99 (0.9-1.0) 5 6 
Sensitivity of QuantiFERON 0.84 (0.78-0.90) 5 
Proportion of new entrants with pre-existing active TB (ie. 
prevalent cases) 
0.0 Assumed
Proportion of IGRA positive new entrants accepting 
chemoprophylaxis 
0.95 (0.3-1.0) 
 
13 
Proportion of IGRA positive new entrants completing 
chemoprophylaxis 
0.85 (0.3-1.0) 14 
Duration of chemoprophylaxis with rifampicin and isoniazid 
(course completed) 
3 months 11 
Duration of chemoprophylaxis with rifampicin and isoniazid 
(course partially completed) 
1.5 months Assumed
Efficacy of 3 months of Rifampicin and Isoniazid 0.65 (0.5-0.8) 2 15 
Efficacy of 1.5 months of Rifampicin and isoniazid (partial 
chemoprophylaxis) 
0.21 (0.1-0.3) 2 2 
Proportion of IGRA positive individuals progressing to active TB 
(post-exposure TB) over 20 years 
0.05 (0.025-0.10) 9 
Proportion of those who are cured of LTBI who can be reinfected 0 Assumed
Proportion of those who are cured of LTBI who can reactivate to 
active TB 
0 Assumed
Proportion of those who are not cured of LTBI who can reactivate 
to active TB (annually) 
0.0025 9 
Proportion of individuals on chemoprophylaxis who develop 
hepatoxicity 
0.002 1 
Proportion of individuals on chemoprophylaxis who develop 
hepatoxicity which resolves 
0.9 Assumed
Proportion of individuals on chemoprophylaxis requiring 
inpatient hospital stay 
0.2 4 16 
Proportion of individuals with active TB accepting treatment 1.0 Assumed
Proportion of individuals with active TB completing therapy 1.0 Assumed
Proportion of individuals with active TB cured 1.0 Assumed
Discount rate 0.035 10 
 
1Refers to the range explored in the univariate sensitivity analysis 
2Data from IUAT study was the basis of an assumed estimate2 
3Estimates for the proportion of IGRA positive individuals progressing to active TB drawn from 
Horsburgh et al which is based on TST data9 
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Supplementary table 3. Costs (2010 pounds sterling) associated with diagnosis and treatment of 
active TB  
 
Active TB cases Base case (range)1 Reference(s) 
Contact tracing 
Contact tracing per contact (£) 
 
482 (241-723) 
 
14 
Mean number of contacts 
examined per primary case 
6.5 (3.25-10) 14 
Mean number of secondary 
active TB cases per index case  
0.2 (0.1-0.3) 14 
Mean number of latent infections 
per primary case of active TB 
disease 
0.18 (0.09-0.27) 17 
   
Inpatient care  
Cost of inpatient episode for 
acute TB (£ per spell) 
 
4012.97 (2006.5-6019.46) 14 18 19 
Proportion of patients with acute 
TB who are admitted 0.53 (0.265-0.795) 
14 
Cost of inpatient care (£ per 
active case) 2126.87 Calculated 
   
Cost of tests 
Costs of culture test (£ per test) 
 
10 
 
14 
Costs of chest X-ray (£ per X-
ray) 
28 13 
Costs of liver functions tests 1 13
Culture tests per case treated 4 13 14 
Chest X-ray per case treated 2 13 14 
Liver functions tests per case 
treated 
4 13 14 
Total cost of tests (£ per TB case 
treated) 
1003 Calculated 
   
Cost of chemotherapy 
Rifampicin (£ per month) 
 
10.76 
 
13 14 
Isoniazid (£ per month) 17.87 13 14 
Pyrazinamide (£ per month) 6.88 13 14 
Ethambutol (£ per month)) 18.48 13 14 
Duration of rifampicin (months) 6 13 14 
Duration of isoniazid (months) 6 13 14 
   
Outpatient care  
Cost of outpatient consultation 
(first visit) 
 
257 
 
13 14 
Cost of outpatient consultation 
(follow-up visit) 
130 13 14 
Cost of TB Nurse home visit  22 13 14 
Number of outpatient clinic visits 
per case treated 
4 13 14 
Visits from TB Nurse per case 
treated 
6 13 14 
Total costs of non-drug 
outpatient care (£ per case 
treated) 
7793 Calculated 
1Refers to the range explored in the univariate sensitivity analysis 
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2In the sensitivity analysis the costs of outpatient care for an active TB case and the tests required were 
considered together (total = 879, range explored  439.5-1318.5).
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Supplementary table 4. Costs (2010 pounds sterling) associated with diagnosis and treatment of 
latent TB infection 
 
 
Active TB cases Base case (range)1 Reference(s) 
 
Cost of screening 
QuantiFERON (test kit, consumables and phlebotomy) 
 
 
45 (22.5-90) 
 
 
13 14 
   
Cost of evaluating positive QuantiFERON 
Cost of outpatient consultation: first visit (£ per visit) 
CXR 
LFT 
Number of outpatient consultation 
Number of CXR 
Number of LFT 
 
257 
28 
1 
1 
1 
1 
 
13 14 
 
Total cost of evaluating positive QuantiFERON 
 
286 (143-429) Calculated 
Cost of follow-up and chemoprophylactic therapy for 
positives undergoing treatment 
Follow up via TB nurses 
 
 
 
22
 
 
 
13 14 
Rifampicin (£ per month) 10.76 13 14 
Isoniazid (£ per month) 17.87 13 14 
Number of TB Nurses appointments 2 13 14 
Duration of rifampicin (months) 3 13 14 
Duration of isoniazid (months) 3 13 14 
Total cost of chemoprophylaxis (£ per course) plus TB nurse 
follow-up 
130 (65-195) Calculated 
Cost of managing a case of chemoprophylaxis induced liver 
injury 
Cost of additional clinic visits and blood tests
 
362 
 
20 
Cost of inpatient stay  1000 20 
 
1Refers to the range explored in the univariate sensitivity analysis 
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Supplementary table 5. Univariate sensitivity analysis of costs (2010 GB pounds) used as input variables in the decision model. (The figures presented are the 
incremental cost-effectiveness ratios (ICERs); moving from lowest to highest ICER indicates decreasing cost-effectiveness. ED = Extended dominance - this the 
situation where the incremental cost-effectiveness ratio (ICER) for a particular screening threshold is higher than for the next most effective strategy (screening 
threshold) and so the higher ICER is removed from the cost-effectiveness analysis. 
 
Parameter 
Screening thresholds for <16 and 16-35 (UK pound sterling per case averted) 
<16 All 
16-35 All 
<16 40 
16-35 40 
<16 40 
16-35 100 
<16 40 
16-35 150 
<16 40 
16-35 
200 
<16 40 
16-35 250 
<16 40 
16-35 300 
<16 40 
16-35 350 
<16 40 
16-35 400 
<16 40 
16-35 450 
<16 40 
16-35 500 
<16 40 
16-35 
500+SSA 
Cost of initial screening 
22.50 
90 
 
44,942.7 
215,929.6 
 
20,771.3 
46,666.7 
 
ED 
ED 
 
15,907.0 
30,642.5 
 
ED 
ED 
 
14,357.4 
25,153.2 
 
ED 
ED 
 
ED 
ED 
 
SD 
SD 
 
ED 
ED 
 
ED 
ED 
 
ED 
ED 
Cost of evaluating of IGRA 
positive new-entrants 
143 
429 
 
 
103,960.2 
99,916.4 
 
 
22,806.1 
36,000.0 
 
 
ED 
ED 
 
 
14,629.5 
27,008.2 
 
 
ED 
ED 
 
 
11,850.9 
24,061.1 
 
 
ED 
ED 
 
 
ED 
ED 
 
 
SD 
SD 
 
 
ED 
ED 
 
 
ED 
ED 
 
 
ED 
ED 
Cost of treating new-entrants 
65 
195 
 
102,754.9 
101,121.7 
 
26,774.5 
32,031.7
 
ED 
ED
 
18,353.2 
23,284.5
 
ED 
ED
 
15,524.0 
20,387.9
 
ED 
ED 
 
ED 
ED
 
SD 
SD
 
ED 
ED
 
ED 
ED
 
ED 
ED 
Cost of active TB OP follow-up 
439.5 
1318.5 
 
102,377.8 
101,498.8 
 
29,842.6 
28,963.6 
 
ED 
ED 
 
21,258.3 
20,379.3 
 
ED 
ED 
 
18,395.5 
17,516.5 
 
ED 
ED 
 
ED 
ED 
 
SD 
SD 
 
ED 
ED 
 
ED 
ED 
 
ED 
ED 
Cost of active TB OP drugs 
111 
333 
 
102,049.3 
101,827.3 
 
29,514.1 
29,292.1 
 
ED 
ED 
 
20,929.8 
20,707.8 
 
ED 
ED 
 
18,067.0 
17,845.0 
 
ED 
ED 
 
ED 
ED 
 
SD 
SD 
 
ED 
ED 
 
ED 
ED 
 
ED 
ED 
Cost of active TB inpatient 
treatment 
2006.5 
6019.46 
 
 
103,001.7 
100,874.9 
 
 
30,466.5 
28,339.6 
 
 
ED 
ED 
 
 
21,882.3 
19,755.4 
 
 
ED 
ED 
 
 
19,019.4 
16,892.5 
 
 
ED 
ED 
 
 
ED 
ED 
 
 
SD 
SD 
 
 
ED 
ED 
 
 
ED 
ED 
 
 
ED 
ED 
Cost of contact tracing  
241 
723 
 
103,504.8 
100,371.8 
 
30,969.6 
27,836.6 
 
ED 
ED 
 
22,385.3 
19,252.3 
 
ED 
ED 
 
19,522.5 
16,389.5 
 
ED 
ED 
 
ED 
ED 
 
SD 
SD 
 
ED 
ED 
 
ED 
ED 
 
ED 
ED 
Cost of Hepatotoxicity with 
chemoprophylaxis  
181 
 
 
101,948.5 
 
 
29,369.7 
 
 
ED 
 
 
20,787.5 
 
 
ED 
 
 
17,925.1 
 
 
ED 
 
 
ED 
 
 
SD 
 
 
ED 
 
 
ED 
 
 
ED 
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1862 101,903.4 29,517.0 ED 20,925.8 ED 18,061.4 ED ED SD ED ED ED 
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Figures 
Supplementary figure 1a. Decision tree used for the health economic analysis (Individuals fully cured of LTBI are assumed to remain free of further infection for 
the 20-year time horizon of the model. *For clarity all “reactivate to active TB subtrees” are shown in figure 1b below). Please note that as data is available on all 
migrants we are able to compute, at each incidence threshold, the number of migrants screened/not screened and subsequently the proportions that are IGRA 
positive and IGRA negative). 
 13
 
 
 14
Footnotes: 
 
1. Individuals are only eligible for screening if they originate from a country which has a TB incidence equal or greater to the screening threshold selected. 
2. In the model all individuals who are fully cured of LTBI are assumed to have cleared infection with Mycobacterium tuberculosis (a terminal node) 
3. Not cured LTBI individuals remain at risk of progressing to active TB in the future 
4. Individuals who develop hepatotoxicity after starting chemoprophylaxis but which subsequently does not resolve are assumed to stop the drug. In the model it is assumed 
that they complete only 4 weeks of treatment and this has neglible efficacy thereby leaving them latently infected and thus at future risk of reactivating to active TB 
5. Individuals who develop hepatotoxicity after starting chemoprophylaxis but which subsequently resolves are assumed to continue the drug. In the model it is assumed that 
they can either complete or not complete treatment with their attendant outcomes 
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Supplementary figure 1b. Decision subtree used to describe the events that occur if an individual reactivates to active TB (although we have shown a branch/node 
for not accepting treatment for active TB, in the model we assume that all individuals do accept treatment for active TB) 
 
 
 
 
Footnotes: 
Individuals who do not accept treatment(*) are represented in the model for completeness but, in reality, it is assumed that no individuals refuse treatment for active TB (ie. 
this is a terminal node) 
Individuals who do not complete treatment(**) are represented in the model for completeness but, in reality, it is assumed that all patients complete treatment 
Individuals who are active TB not cured(***) are represented in the model for completeness but, in reality, it is assumed that as they have all completed treatment none of 
them move into the active TB not cured group 
 16
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